showed that continuous subcutaneous infusion of the TLR4 agonist LPS in mice for four weeks increased body weight to the same extent as HFD, with a similar distribution between visceral and subcutaneous adipose depots but did not trigger NAFLD. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.